263893-81-8 Usage
General Description
"Benzenemethanamine, 3-ethoxy-alpha-methyl-, (alphaR)- (9CI)" is a complex organic compound that belongs to the class of chemicals known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom next to the carboxylate group (alpha carbon). Most notably, this chemical is used mainly in the field of chemistry for research purposes. The 'alphaR' in its name alludes to the chirality or the specific spatial arrangement of its atoms, a key factor in its chemical behavior. The '9CI' indicates it is referenced in the ninth collective index, a system used to categorize and identify chemical substances.
Check Digit Verification of cas no
The CAS Registry Mumber 263893-81-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,3,8,9 and 3 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 263893-81:
(8*2)+(7*6)+(6*3)+(5*8)+(4*9)+(3*3)+(2*8)+(1*1)=178
178 % 10 = 8
So 263893-81-8 is a valid CAS Registry Number.
263893-81-8Relevant articles and documents
N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG
-
Page/Page column 184, (2012/12/14)
The invention provides molecular entities that bind with high affinity to PPARG (PPAR3), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
